"Ozempic face" is a colloquial term for facial volume loss observed in some patients during rapid weight loss with GLP-1 medications. The phenomenon has been widely discussed in popular media, but is frequently misunderstood. This article explains what it is, who is affected, and what the evidence says about prevention.
What is "Ozempic face"?
Ozempic face describes the gaunt, hollowed, or aged appearance some patients develop in the cheeks, temples, and around the eyes during significant weight loss. It is not caused by semaglutide directly — rather, it is a consequence of rapid loss of subcutaneous and deep facial fat that occurs alongside body fat loss.
Similar changes occur with any rapid weight loss regimen — bariatric surgery, very-low-calorie diets, intense intermittent fasting. The visibility of these changes with GLP-1 medications is partly because patients are losing significant weight (often 15-25%+) over relatively short periods.
Who is most at risk?
- Patients over 40, where facial fat depots are thinner to begin with
- Patients losing >20% of starting body weight
- Patients with already lean baseline body composition
- Patients with rapid weight loss (>1.5 kg/week)
Evidence-based prevention strategies
No medication or intervention has been proven to specifically prevent Ozempic face during GLP-1 treatment. However, general strategies that preserve facial volume during weight loss have evidence behind them:
- Slower weight loss rate (1-2 lbs/week target) — discuss dose adjustments with your prescriber
- Adequate protein intake (>1g/kg body weight) preserves lean mass including facial muscle
- Resistance training preserves overall lean tissue
- Adequate hydration and electrolytes maintain skin turgor
- Skin-care including SPF protects collagen integrity